Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Vivus Inc.

Latest From Vivus Inc.

If Orexigen Disappears, Who's Left In The Obesity Market?

Orexigen, one of just five biopharma companies with an obesity product on the market, has become concerned about its ability to stay in business. Even so, the misfortune of several firms hasn't dissuaded others, including Novo Nordisk, from investing in the potentially large weight-loss market.

Business Strategies Commercial

Gelesis100 Weight Loss Pill Wins Applause But Pharma Not Threatened – Yet

The commercial contest between satiety-producing weight loss products and evolving pharmacological medicines looks set to intensify after encouraging top-line pivotal data for Gelesis' capsule.

Commercial Comparative Effectiveness

Novo Nordisk Will Eat Itself In Obesity

The Danish diabetes specialist is forging ahead with pivotal trials for its latest GLP-1 offering semaglutide in obesity after highly impressive Phase II efficacy data, but is likely to take the biggest market share from its own product, Saxenda.

Companies Analysis

Deals Shaping The Medical Industry, February 2017

Derived from Strategic Transactions, Informa’s premium source for tracking life sciences deal activity, the Dealmaking column is a survey of recent health care transactions listed by relevant industry segment – In Vitro Diagnostics, Medical Devices, and Pharmaceuticals – and then categorized by type – Acquisition, Alliance, or Financing. This month’s column covers deals announced in January 2017

Deals BioPharmaceutical
See All

Company Information

  • Industry
  • Biotechnology
  • Pharmaceuticals
  • Therapeutic Areas
  • Gynecological, Urological
  • Metabolic Disorders
  • Respiratory, Pulmonary
  • Alias(es)
  • Ownership
  • Public
  • Headquarters
  • Worldwide
    • North America
      • USA
  • Parent & Subsidiaries
  • Vivus Inc.
  • Senior Management
  • Thomas B King, Interim CEO
    Mark K Oki, CFO & Chief Accounting Officer
    Deborah W Larsen, PhD, Chief Commercial Officer
    John L Slebir, SVP, Bus. Dev. & General Counsel
    Santosh T Varghese, MD, CMO
  • Contact Info
  • Vivus Inc.
    Phone: (650) 934-5200
    900 E. Hamilton Ave
    Suite 550
    Campbell, CA 95008